BR112019003543A2 - suspensão celular para uso no tratamento da doença arterial periférica da extremidade inferior - Google Patents

suspensão celular para uso no tratamento da doença arterial periférica da extremidade inferior

Info

Publication number
BR112019003543A2
BR112019003543A2 BR112019003543-5A BR112019003543A BR112019003543A2 BR 112019003543 A2 BR112019003543 A2 BR 112019003543A2 BR 112019003543 A BR112019003543 A BR 112019003543A BR 112019003543 A2 BR112019003543 A2 BR 112019003543A2
Authority
BR
Brazil
Prior art keywords
cell suspension
peripheral arterial
arterial disease
population
lower extremity
Prior art date
Application number
BR112019003543-5A
Other languages
English (en)
Inventor
Robert Barclay Dupere Jonathan
De Jong Liesbeth
J. Wagena Edwin
Original Assignee
Rexgenero Biosciences S.L.
Servicio Andaluz De Salud
Fundación Pública Andaluza Progreso Y Salud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rexgenero Biosciences S.L., Servicio Andaluz De Salud, Fundación Pública Andaluza Progreso Y Salud filed Critical Rexgenero Biosciences S.L.
Publication of BR112019003543A2 publication Critical patent/BR112019003543A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • External Artificial Organs (AREA)

Abstract

a presente invenção refere-se a uma suspensão celular de leucócitos derivados de medula óssea adulta, autólogos ou halogênicos, de preferência, autólogos, de preferência, derivados da crista do ílio (ou crista ilíaca), enriquecida para células mononucleares, significando que mais de 25% dos leucócitos (wbcs) presentes na suspensão celular são células mononucleares, e compreendendo: a células mononucleares (mnc) selecionadas da lista que compreende ou consiste em: i. uma população de linfócitos; ii. uma população de monócitos; e iii. uma população de células-tronco hematopoiéticas que expressam cd34; e em que a suspensão celular compreende ainda: b. granulócitos; para uso no tratamento ou melhoria da doença arterial periférica dos membros inferiores.
BR112019003543-5A 2016-08-26 2017-08-28 suspensão celular para uso no tratamento da doença arterial periférica da extremidade inferior BR112019003543A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382405.5 2016-08-26
EP16382405 2016-08-26
PCT/EP2017/071580 WO2018037134A1 (en) 2016-08-26 2017-08-28 Cell suspension for use in the treatment of lower extremity peripheral artery disease

Publications (1)

Publication Number Publication Date
BR112019003543A2 true BR112019003543A2 (pt) 2019-05-21

Family

ID=56842774

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019003543-5A BR112019003543A2 (pt) 2016-08-26 2017-08-28 suspensão celular para uso no tratamento da doença arterial periférica da extremidade inferior

Country Status (15)

Country Link
US (2) US10869886B2 (pt)
EP (1) EP3504322A1 (pt)
JP (2) JP7260878B2 (pt)
KR (1) KR20190053198A (pt)
CN (1) CN110168077B (pt)
AU (1) AU2017315174B2 (pt)
BR (1) BR112019003543A2 (pt)
CA (1) CA3035076A1 (pt)
EA (1) EA201990583A1 (pt)
IL (1) IL265025B1 (pt)
MX (1) MX2019002288A (pt)
SA (1) SA519401187B1 (pt)
SG (1) SG11201901594RA (pt)
WO (1) WO2018037134A1 (pt)
ZA (1) ZA201901826B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9402707B2 (en) 2008-07-22 2016-08-02 Neuravi Limited Clot capture systems and associated methods
EP2629684B1 (en) 2010-10-22 2018-07-25 Neuravi Limited Clot engagement and removal system
US11253278B2 (en) 2014-11-26 2022-02-22 Neuravi Limited Clot retrieval system for removing occlusive clot from a blood vessel
EP3504322A1 (en) * 2016-08-26 2019-07-03 Rexgenero Biosciences S.L. Cell suspension for use in the treatment of lower extremity peripheral artery disease
US10842498B2 (en) * 2018-09-13 2020-11-24 Neuravi Limited Systems and methods of restoring perfusion to a vessel
US11406416B2 (en) 2018-10-02 2022-08-09 Neuravi Limited Joint assembly for vasculature obstruction capture device
US11871946B2 (en) 2020-04-17 2024-01-16 Neuravi Limited Clot retrieval device for removing clot from a blood vessel
US11937836B2 (en) 2020-06-22 2024-03-26 Neuravi Limited Clot retrieval system with expandable clot engaging framework
US11395669B2 (en) 2020-06-23 2022-07-26 Neuravi Limited Clot retrieval device with flexible collapsible frame
US11439418B2 (en) 2020-06-23 2022-09-13 Neuravi Limited Clot retrieval device for removing clot from a blood vessel
CN114561352A (zh) * 2022-03-24 2022-05-31 青岛市中心血站 从无偿献血全血采集装置中分离单个核细胞的方法
WO2024099865A1 (en) * 2022-11-08 2024-05-16 Servicio Andaluz De Salud Cell suspension for use in the treatment of stroke patients

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110076255A1 (en) * 2005-11-07 2011-03-31 Pecora Andrew L Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
CN107595889A (zh) * 2008-09-12 2018-01-19 克里奥普拉斯低温生物有限公司 缺血性组织的细胞疗法
US20150157663A1 (en) * 2012-01-19 2015-06-11 Snu R&Db Foundation Pharmaceutical Composition Comprising Human-Blood-Derived-Cell Mass
JP2015508101A (ja) * 2012-02-21 2015-03-16 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Ｃｄ３４＋細胞を含む薬学的組成物
EP3504322A1 (en) * 2016-08-26 2019-07-03 Rexgenero Biosciences S.L. Cell suspension for use in the treatment of lower extremity peripheral artery disease

Also Published As

Publication number Publication date
JP2022166251A (ja) 2022-11-01
AU2017315174B2 (en) 2023-11-09
IL265025A (pt) 2019-04-30
US20180055884A1 (en) 2018-03-01
CN110168077B (zh) 2024-06-14
CA3035076A1 (en) 2018-03-01
JP7260878B2 (ja) 2023-04-19
US10869886B2 (en) 2020-12-22
JP2019528325A (ja) 2019-10-10
US20210161960A1 (en) 2021-06-03
ZA201901826B (en) 2019-12-18
KR20190053198A (ko) 2019-05-17
IL265025B1 (en) 2024-10-01
SG11201901594RA (en) 2019-03-28
MX2019002288A (es) 2019-09-18
WO2018037134A1 (en) 2018-03-01
CN110168077A (zh) 2019-08-23
SA519401187B1 (ar) 2023-01-09
AU2017315174A1 (en) 2019-04-18
EP3504322A1 (en) 2019-07-03
EA201990583A1 (ru) 2019-08-30

Similar Documents

Publication Publication Date Title
BR112019003543A2 (pt) suspensão celular para uso no tratamento da doença arterial periférica da extremidade inferior
Marycz et al. Endurance exercise mobilizes developmentally early stem cells into peripheral blood and increases their number in bone marrow: implications for tissue regeneration
MX2023007726A (es) Antifolatos poliglutamados alfa y gamma-d y sus usos.
WO2007140472A3 (en) Cd127 expression inversely correlates with foxp3 and suppressive function of cd4+ tregs
BRPI0921799B8 (pt) compostos que expandem células-tronco hematopoétticas
BRPI0512814A (pt) exosomas imunossupressivas
BR112012030818A2 (pt) "derivados de ácido c-3 betulínico modificado como inibidores da maturação do hiv"
BR112021019349A2 (pt) Células-tronco preparadas altamente funcionais
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
BR112016009898A2 (pt) células-tronco/progenitoras hematopoiéticas e efetoras não-t modificadas e usos das mesmas
CO6950476A2 (es) Derivados de 8-carbamoil-2-(2,3- pirid- 6- ilo di sustituido) -1,2,3,4 -tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes
BR112018074352A2 (pt) partículas de nanoalume contendo um agente de dimensionamento
BR112018067597A8 (pt) célula progenitora de fígado adulto, população celular, material biológico, composição, método para avaliar a eficácia, o metabolismo, a estabilidade e/ou a toxicidade de um ou mais compostos, uso da célula ou população celular e kit
BR112012032979A2 (pt) composição para limpeza límpida, de baixa irritação, e com ph relativamente baixo
BR112015028278A2 (pt) processo para a preparação de eritrócitos carregados com uma ou mais substâncias de interesse farmacêutico e eritrócitos assim obtidos
BR112015003399A2 (pt) métodos e composições úteis para melhorar a saúde óssea e articular
BR112012013034A2 (pt) métodos e aparelhos para segregação de partículas, incluindo a segregação e a proliferação de células fetais e células-tronco
BR112018010499A8 (pt) método para replicar um vírus, vírus, método para produzir uma composição de vacina, composição de vacina, população de células in vitro, método para produzir uma população de células, e população de células
WO2018088875A3 (ko) 외래 미토콘드리아를 포함하는 자연살해세포 및 이를 포함하는 약학적 조성물
BR112019017393A2 (pt) formulações de evolocumab de baixa viscosidade, alta concentração e métodos para produzir as mesmas
Barro et al. A double‐virally‐inactivated (intercept–solvent/detergent) human platelet lysate for in vitro expansion of human mesenchymal stromal cells
BR112019024667A2 (pt) Uso de um agente bioativo, e, de uma composição
AR096942A1 (es) Métodos para promocionar el desarrollo neuronal y/o la salud
Froushani et al. Conditioned medium of mesenchymal stem cells pulsed with theobromine can instruct anti-inflammatory neutrophils
BR112014027333A2 (pt) composição, métodos de tratamento ou melhora, de prevenção, e, de diagnóstico de uma condição prejudicial que está associada com o teor elevado de sulfato de heparano em um indivíduo que foi o receptor de um órgão, tecido ou células transplantados

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]